Elevance Sued Over Zepbound Coverage Denials for Sleep Apnea

Elevance Health Inc. was hit with a proposed class action by a woman who says the insurer wrongly refuses to cover the weight-loss drug Zepbound for patients who need it to treat obstructive sleep ... Read More

CVS Caremark faces class-action lawsuit over Zepbound, Wegovy coverage

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. Read More

Novo Nordisk eyes broader role for its obesity drugs from sleep apnea to knees

Novo Nordisk, looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its next-generation obesity drugs can treat a broader range of related conditions ... Read More

Lilly Sees Obesity Drug Leadership Beyond US as It Leans on Consumer-Focused Strategy

Novo Nordisk was first to market with a highly effective GLP-1 obesity drug in 2021, but Lilly has pulled ahead this year, with total prescriptions for Mounjaro now surpassing Novo's Wegovy. Surging ... Read More

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. (LLY) , is false or misleading. Read More

Serena Williams reveals she uses GLP-1 weight loss drug Zepbound: 'I just could never get back to where I needed to be’

Serena Williams is opening up about her fitness journey, revealing that she has lost 31 pounds using the injectable GLP-1 weight loss drug Zepbound, combined with consistent exercise and a healthy ... Read More